Top-Rated StocksTop-RatedNASDAQ:CYTK Cytokinetics (CYTK) Stock Price, News & Analysis → Nvidia CEO Says It Will Be “the Next Revolution” Beyond AI (From Banyan Hill Publishing) (Ad) Free CYTK Stock Alerts $62.53 -2.81 (-4.30%) (As of 04/29/2024 ET) Add Compare Share Share Today's Range$62.20▼$65.0050-Day Range$62.53▼$80.9952-Week Range$25.98▼$110.25Volume1.29 million shsAverage Volume2.88 million shsMarket Capitalization$6.54 billionP/E RatioN/ADividend YieldN/APrice Target$79.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Cytokinetics alerts: Email Address Cytokinetics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.87 Rating ScoreUpside/Downside26.9% Upside$79.33 Price TargetShort InterestBearish13.91% of Float Sold ShortDividend StrengthN/ASustainability-0.83Upright™ Environmental ScoreNews Sentiment0.37Based on 14 Articles This WeekInsider TradingSelling Shares$9.27 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.50) to ($3.15) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.11 out of 5 starsMedical Sector278th out of 918 stocksPharmaceutical Preparations Industry121st out of 422 stocks 4.4 Analyst's Opinion Consensus RatingCytokinetics has received a consensus rating of Moderate Buy. The company's average rating score is 2.87, and is based on 13 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageCytokinetics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted13.91% of the float of Cytokinetics has been sold short.Short Interest Ratio / Days to CoverCytokinetics has a short interest ratio ("days to cover") of 6.9.Change versus previous monthShort interest in Cytokinetics has recently increased by 6.12%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCytokinetics does not currently pay a dividend.Dividend GrowthCytokinetics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCytokinetics has received a 71.40% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health", "Clinical research services for physiological diseases ", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Cytokinetics is -0.83. Previous Next 1.9 News and Social Media Coverage News SentimentCytokinetics has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Cytokinetics this week, compared to 6 articles on an average week.Search InterestOnly 6 people have searched for CYTK on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Cytokinetics to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cytokinetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,269,877.00 in company stock.Percentage Held by InsidersOnly 3.40% of the stock of Cytokinetics is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cytokinetics are expected to grow in the coming year, from ($4.50) to ($3.15) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cytokinetics is -11.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cytokinetics is -11.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable ProsperityCharles Payne’s Gift to Stock InvestorsRight now, millions of good honest folks are feeling the squeeze. Last year's terrible market did a number on their accounts. Stock values plunged. Retirement accounts lost too.Watch Insider's Advantage Event Tuesday at 4:00 PM ET About Cytokinetics Stock (NASDAQ:CYTK)Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.Read More CYTK Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CYTK Stock News HeadlinesApril 26, 2024 | insidertrades.comJohn T. Henderson Sells 10,562 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) StockApril 10, 2024 | insidertrades.comCytokinetics, Incorporated (NASDAQ:CYTK) EVP Sells $2,422,877.55 in StockApril 30, 2024 | Banyan Hill Publishing (Ad)Nvidia CEO Says It Will Be “the Next Revolution” Beyond AINvidia’s CEO calls it the “next amazing revolution” … and even declared it “is going to be flat out of the biggest [revolution] ever.” Jeff Bezos, Bill Gates, and Mark Zuckerberg have invested billions in it.April 29, 2024 | globenewswire.comCytokinetics to Host Investor Event and Conference Call to Discuss the Primary Results From SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 CongressApril 28, 2024 | barrons.comCytokinetics Inc.April 28, 2024 | nasdaq.comJune 7th Options Now Available For Cytokinetics (CYTK)April 27, 2024 | americanbankingnews.comCytokinetics, Incorporated (NASDAQ:CYTK) Given Consensus Rating of "Moderate Buy" by BrokeragesApril 26, 2024 | marketwatch.comCytokinetics Taps Sung Lee as Permanent CFOApril 30, 2024 | Banyan Hill Publishing (Ad)Nvidia CEO Says It Will Be “the Next Revolution” Beyond AINvidia’s CEO calls it the “next amazing revolution” … and even declared it “is going to be flat out of the biggest [revolution] ever.” Jeff Bezos, Bill Gates, and Mark Zuckerberg have invested billions in it.April 26, 2024 | americanbankingnews.comCytokinetics, Incorporated (NASDAQ:CYTK) Director John T. Henderson Sells 10,562 Shares of StockApril 24, 2024 | globenewswire.comCytokinetics to Announce First Quarter Results on May 8, 2024April 11, 2024 | uk.investing.comCytokinetics to present phase 3 trial results for heart drug at Heart Failure 2024April 11, 2024 | uk.investing.comCytokinetics EVP sells over $2.4m in company stockApril 10, 2024 | globenewswire.comCytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 CongressApril 10, 2024 | globenewswire.comCytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 CongressApril 9, 2024 | finance.yahoo.comEVP Research & Development Fady Malik Sells Shares of Cytokinetics Inc (CYTK)April 5, 2024 | markets.businessinsider.comBuy Rating Affirmed for Cytokinetics Amid Strong Aficamten Trial ResultsApril 5, 2024 | markets.businessinsider.comBuy Rating Affirmed on Cytokinetics Amid Promising Aficamten Clinical ResultsApril 5, 2024 | globenewswire.comCytokinetics Presents Additional 48-Week Data From FOREST-HCM, the Open Label Extension Clinical Study of Aficamten, at The American College of Cardiology 73ʳᵈ Annual Scientific SessionApril 3, 2024 | benzinga.com$100 Invested In Cytokinetics 5 Years Ago Would Be Worth This Much TodayApril 2, 2024 | globenewswire.comCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 1, 2024 | globenewswire.comCytokinetics to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceApril 1, 2024 | seekingalpha.comCytokinetics, Incorporated: Buyout Speculation PersistsMarch 30, 2024 | finance.yahoo.comCYTK Apr 2024 60.000 callMarch 27, 2024 | msn.comCytokinetics gains amid renewed takeover speculationMarch 25, 2024 | globenewswire.comCytokinetics Announces Four Upcoming Presentations at the American College of Cardiology 73rd Annual Scientific SessionMarch 18, 2024 | investorplace.com7 Biotech Stocks Ready to Ride the Sector's ResurgenceSee More Headlines Receive CYTK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cytokinetics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2024Today4/29/2024Next Earnings (Confirmed)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CYTK CUSIPN/A CIK1061983 Webwww.cytokinetics.com Phone(650) 624-3000Fax650-624-3010Employees423Year Founded1997Price Target and Rating Average Stock Price Target$79.33 High Stock Price Target$108.00 Low Stock Price Target$50.00 Potential Upside/Downside+26.9%Consensus RatingModerate Buy Rating Score (0-4)2.87 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)($5.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-526,240,000.00 Net Margins-6,988.63% Pretax Margin-6,988.63% Return on EquityN/A Return on Assets-65.08% Debt Debt-to-Equity RatioN/A Current Ratio6.12 Quick Ratio6.12 Sales & Book Value Annual Sales$7.53 million Price / Sales868.44 Cash FlowN/A Price / Cash FlowN/A Book Value($3.94) per share Price / Book-15.87Miscellaneous Outstanding Shares104,580,000Free Float101,020,000Market Cap$6.54 billion OptionableOptionable Beta0.68 Social Links 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Robert I. Blum (Age 60)CEO, President, Principal Financial Officer & Director Comp: $1.33MMr. Robert C. Wong (Age 56)VP & Chief Accounting Officer Comp: $495.72kDr. Fady Ibraham Malik FACC (Age 60)M.D., Ph.D., Executive Vice President of Research & Development Comp: $839.66kMr. Andrew M. Callos (Age 55)Executive VP & Chief Commercial Officer Comp: $752.84kDr. James A. Spudich Ph.D. (Age 82)Co-Founder & Member of Scientific Advisory Board Comp: $21.94kMr. Jeff LotzVice President of Sales & OperationsMr. Matt YangVice President of Corporate Finance and Financial Planning & AnalysisMr. Steven M. Cook (Age 65)Senior Vice President of Global Supply Chain Operations & Technical Operations Ms. Kari K. Loeser J.D.VP & Chief Compliance OfficerMr. John O. Faurescu Esq.VP, Associate General Counsel & Corporate SecretaryMore ExecutivesKey CompetitorsJazz PharmaceuticalsNASDAQ:JAZZElanco Animal HealthNYSE:ELANViking TherapeuticsNASDAQ:VKTXIntra-Cellular TherapiesNASDAQ:ITCIIonis PharmaceuticalsNASDAQ:IONSView All CompetitorsInsiders & InstitutionsPrincipal Financial Group Inc.Sold 89,616 shares on 4/29/2024Ownership: 0.413%China Universal Asset Management Co. Ltd.Bought 8,429 shares on 4/29/2024Ownership: 0.019%Pinnacle Associates Ltd.Sold 1,191 shares on 4/26/2024Ownership: 0.246%Peregrine Capital Management LLCSold 5,121 shares on 4/26/2024Ownership: 0.121%Yousif Capital Management LLCSold 3,496 shares on 4/26/2024Ownership: 0.043%View All Insider TransactionsView All Institutional Transactions CYTK Stock Analysis - Frequently Asked Questions Should I buy or sell Cytokinetics stock right now? 15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last twelve months. There are currently 2 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CYTK shares. View CYTK analyst ratings or view top-rated stocks. What is Cytokinetics' stock price target for 2024? 15 equities research analysts have issued 1-year price targets for Cytokinetics' shares. Their CYTK share price targets range from $50.00 to $108.00. On average, they predict the company's share price to reach $79.33 in the next year. This suggests a possible upside of 26.9% from the stock's current price. View analysts price targets for CYTK or view top-rated stocks among Wall Street analysts. How have CYTK shares performed in 2024? Cytokinetics' stock was trading at $83.49 on January 1st, 2024. Since then, CYTK shares have decreased by 25.1% and is now trading at $62.53. View the best growth stocks for 2024 here. Are investors shorting Cytokinetics? Cytokinetics saw a increase in short interest in April. As of April 15th, there was short interest totaling 14,040,000 shares, an increase of 6.1% from the March 31st total of 13,230,000 shares. Based on an average daily volume of 2,030,000 shares, the days-to-cover ratio is presently 6.9 days. Approximately 13.9% of the shares of the stock are short sold. View Cytokinetics' Short Interest. When is Cytokinetics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our CYTK earnings forecast. How can I listen to Cytokinetics' earnings call? Cytokinetics will be holding an earnings conference call on Wednesday, May 8th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link. How were Cytokinetics' earnings last quarter? Cytokinetics, Incorporated (NASDAQ:CYTK) announced its quarterly earnings data on Tuesday, February, 27th. The biopharmaceutical company reported ($1.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.03) by $0.35. The biopharmaceutical company had revenue of $1.70 million for the quarter, compared to the consensus estimate of $7.62 million. Cytokinetics's revenue was down 10.5% on a year-over-year basis. During the same quarter last year, the company earned ($1.45) EPS. What ETFs hold Cytokinetics' stock? ETFs with the largest weight of Cytokinetics (NASDAQ:CYTK) stock in their portfolio include Tema Cardiovascular and Metabolics ETF (HRTS), Principal Healthcare Innovators ETF (BTEC), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Fidelity Disruptive Medicine ETF (FMED), SPDR S&P Biotech ETF (XBI), VanEck Biotech ETF (BBH), Direxion Daily S&P Biotech Bull 3x Shares (LABU) and Invesco Nasdaq Biotechnology ETF (IBBQ). What guidance has Cytokinetics issued on next quarter's earnings? Cytokinetics issued an update on its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided EPS guidance of for the period. The company issued revenue guidance of $3.0 million-$5.0 million, compared to the consensus revenue estimate of $28.5 million. What is Robert I. Blum's approval rating as Cytokinetics' CEO? 16 employees have rated Cytokinetics Chief Executive Officer Robert I. Blum on Glassdoor.com. Robert I. Blum has an approval rating of 64% among the company's employees. What other stocks do shareholders of Cytokinetics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Novavax (NVAX), Amgen (AMGN), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), TherapeuticsMD (TXMD) and Gilead Sciences (GILD). Who are Cytokinetics' major shareholders? Cytokinetics' stock is owned by a number of retail and institutional investors. Top institutional investors include Principal Financial Group Inc. (0.41%), Pinnacle Associates Ltd. (0.25%), Peregrine Capital Management LLC (0.12%), New York State Teachers Retirement System (0.11%), Amalgamated Bank (0.05%) and Yousif Capital Management LLC (0.04%). Insiders that own company stock include B Lynne Parshall, Ching Jaw, David Cragg, Edward M Md Kaye, Fady Ibraham Malik, John T Henderson, L Patrick Gage, Mark A Schlossberg, Muna Bhanji, Robert I Blum, Robert I Blum, Robert Wong, Sandford D Smith, Santo J Costa and Wendall Wierenga. View institutional ownership trends. How do I buy shares of Cytokinetics? Shares of CYTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CYTK) was last updated on 4/30/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingCharles Payne’s Gift to Stock InvestorsUnstoppable ProsperityProtect Your Bank Account Before It’s Too LateWeiss RatingsHe Is Giving Away BitcoinCrypto Swap ProfitsElon Musk Secret Crypto Plot ExposedCrypto 101 Media4 coins to be the “Next Bitcoin”True Market InsidersForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytokinetics, Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
